These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34758691)

  • 1. Application in Gene Editing in Ovarian Cancer Therapy.
    Luo S; Wang Y; Tao Y; Li S; Wang Z; He W; Wang H; Wang N; Xu J; Song H
    Cancer Invest; 2022 Apr; 40(4):387-399. PubMed ID: 34758691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNAs and ovarian cancer: An overview.
    Deb B; Uddin A; Chakraborty S
    J Cell Physiol; 2018 May; 233(5):3846-3854. PubMed ID: 28703277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of miRNA in Ovarian Cancer: an Overview.
    Zhao L; Liang X; Wang L; Zhang X
    Reprod Sci; 2022 Oct; 29(10):2760-2767. PubMed ID: 34973152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
    Feng LY; Li L
    J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
    Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
    Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
    Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
    BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer.
    Liu J; Xu F; Cheng W; Gao L
    Exp Cell Res; 2020 Oct; 395(2):112235. PubMed ID: 32805252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer.
    Liu L; Zeng Z; Yi J; Zuo L; Lv J; Yuan J; Lin Z; Luo R; Feng X
    Cancer Biomark; 2019; 24(2):213-221. PubMed ID: 30614797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.
    Adachi M; Masugi Y; Yamazaki K; Emoto K; Kobayashi Y; Tominaga E; Banno K; Aoki D; Sakamoto M
    Jpn J Clin Oncol; 2020 Jun; 50(6):643-652. PubMed ID: 32211793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer.
    Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM
    Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.